Solifenacin-d5 succinate | CAS#unknown | Solifenacin internal standard

MedKoo Cat#: 465315 | Name: Solifenacin-d5 succinate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Solifenacin-d5 succinate is intended for use as an internal standard for the quantification of solifenacin by GC- or LC-MS. Solifenacin is a competitive antagonist of M1, M2, and M3 muscarinic acetylcholine receptors (Kis = 25, 125, and 10 nM, respectively, for the human receptors). It inhibits calcium mobilization induced by carbamoylcholine (carbachol) in isolated guinea pig detrusor muscle cells (Ki = 4 nM). Solifenacin inhibits carbachol-induced contraction of isolated guinea pig urinary bladder smooth muscle. In vivo, solifenacin (0.03-1 mg/kg) inhibits carbachol-induced increases in urinary bladder pressure in anesthetized rats. Formulations containing solifenacin have been used in the treatment of overactive bladder.

Chemical Structure

Solifenacin-d5 succinate

CAS#unknown

Theoretical Analysis

MedKoo Cat#: 465315

Name: Solifenacin-d5 succinate

CAS#: unknown

Chemical Formula: C27H27D5N2O6

Exact Mass: 485.2574

Molecular Weight: 485.59

Elemental Analysis: C, 66.78; H, 7.68; N, 5.77; O, 19.77

Price and Availability

Size	Price	Availability	Quantity
1mg	USD 500.00	2 Weeks
5mg	USD 1,300.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Solifenacin-d5 succinate; Solifenacin d5 succinate;

IUPAC/Chemical Name

(R)-quinuclidin-3-yl (S)-1-(phenyl-d5)-3,4-dihydroisoquinoline-2(1H)-carboxylate succinate

InChi Key

RXZMMZZRUPYENV-BCZWPACGSA-N

InChi Code

InChI=1S/C23H26N2O2.C4H6O4/c26-23(27-21-16-24-13-10-18(21)11-14-24)25-15-12-17-6-4-5-9-20(17)22(25)19-7-2-1-3-8-19;5-3(6)1-2-4(7)8/h1-9,18,21-22H,10-16H2;1-2H2,(H,5,6)(H,7,8)/t21-,22-;/m0./s1/i1D,2D,3D,7D,8D;

SMILES Code

O=C(N1[C@H](C2=CC=CC=C2CC1)C3=C(C([2H])=C(C([2H])=C3[2H])[2H])[2H])O[C@H]4CN5CCC4CC5.OC(CCC(O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 485.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mirzaei M, Daneshpajooh A, Anvari SO, Dozchizadeh S, Teimorian M. Evaluation of the Clinical Efficacy and Complications of Duloxetine in Comparison to Solifenacin in the Treatment of Overactive Bladder Disease in Women: A Randomized Clinical Trial. Urol J. 2021 Aug 3. doi: 10.22037/uj.v18i.6274. Epub ahead of print. PMID: 34346046. 2: Shi C, Zhou D, Yu W, Jiao W, Shi G, Wang Y. Efficacy of Yun-Type Optimized Pelvic Floor Training Therapy for Middle-Aged Women With Severe Overactive Bladder: A Randomized Clinical Trial. Front Surg. 2021 Jul 14;8:670123. doi: 10.3389/fsurg.2021.670123. PMID: 34336915; PMCID: PMC8316598. 3: Jin H, Shi L, Yin J, Yu J, Jiang M, Liu F, Zhang J, Zhu Y, Zou C, Yang H. The bioequivalence of a single dose of a generic solifenacin succinate tablet or vesicare in fasting or postprandial healthy Chinese adults. Int J Clin Pharmacol Ther. 2021 Jul 26. doi: 10.5414/CP203860. Epub ahead of print. PMID: 34308834. 4: Duong V, Iwamoto A, Pennycuff J, Kudish B, Iglesia C. A systematic review of neurocognitive dysfunction with overactive bladder medications. Int Urogynecol J. 2021 Jul 2. doi: 10.1007/s00192-021-04909-5. Epub ahead of print. PMID: 34213600. 5: Fayed AS, Hegazy MA, Kamel EB, Eissa MS. Smart Mathematical Manipulation of Spectral Signals: Stability Indicating, for the Estimation of Solifenacin Succinate: Anti-Muscarinic Drug, in Existence of its Acid Degradation Product. J AOAC Int. 2021 Jun 30:qsab080. doi: 10.1093/jaoacint/qsab080. Epub ahead of print. PMID: 34190982. 6: Zhang Y, Wang S, Zu S, Zhang C. Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study. PLoS One. 2021 Jun 23;16(6):e0253040. doi: 10.1371/journal.pone.0253040. PMID: 34161360; PMCID: PMC8221460. 7: Lanter JC, Chen AY, Williamson T, Koenig G, Blain JF, Burnett DA. Discovery of quinuclidine modulators of cellular progranulin. Bioorg Med Chem Lett. 2021 Sep 1;47:128209. doi: 10.1016/j.bmcl.2021.128209. Epub 2021 Jun 18. PMID: 34153473. 8: Chess-Williams R, McDermott C, Sellers DJ, West EG, Mills KA. Chronic psychological stress and lower urinary tract symptoms. Low Urin Tract Symptoms. 2021 Jun 16. doi: 10.1111/luts.12395. Epub ahead of print. PMID: 34132480. 9: Peng HY, Lai CY, Hsieh MC, Lin TB. Solifenacin/Mirabegron Induces an Acute Compliance Increase in the Filling Phase of the Capacity-Reduced Urinary Bladder: A Pressure-Volume Analysis in Rats. Front Pharmacol. 2021 May 26;12:657959. doi: 10.3389/fphar.2021.657959. PMID: 34122078; PMCID: PMC8188241. 10: Soliman MG, El-Abd S, El-Gamal OM, Raheem AA, Abou-Ramadan AR, El-Abd AS. Mirabegron versus Solifenacin in Children with Overactive Bladder: Prospective Randomized Single-Blind Controlled Trial. Urol Int. 2021 May 19:1-7. doi: 10.1159/000515992. Epub ahead of print. PMID: 34010843. 11: Vibegron (Gemtesa) for overactive bladder. Med Lett Drugs Ther. 2021 May 3;63(1623):67-69. PMID: 33976098. 12: Wang CC, Lee CL, Hwang YT, Kuo HC. Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder. Low Urin Tract Symptoms. 2021 May 6. doi: 10.1111/luts.12384. Epub ahead of print. PMID: 33960119. 13: Nofuji S, Kyoda Y, Fukuta F, Kobayashi K, Wanifuchi A, Shinkai N, Ichihara K, Tanaka T, Masumori N. [A Case of Detrusor Hyperactivity with Impaired Contractility (DHIC) after Transverse Myelitis]. Hinyokika Kiyo. 2021 Mar;67(3):109-112. Japanese. doi: 10.14989/ActaUrolJap_67_3_109. PMID: 33957031. 14: Kachru N, Holmes HM, Johnson ML, Chen H, Aparasu RR. Antimuscarinic use among older adults with dementia and overactive bladder: a Medicare beneficiaries study. Curr Med Res Opin. 2021 Aug;37(8):1303-1313. doi: 10.1080/03007995.2021.1920899. Epub 2021 May 13. PMID: 33890538. 15: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Solifenacin. 2021 Apr 19. PMID: 30000729. 16: Kim SC, Park M, Chae C, Yoon JH, Kwon T, Park S, Moon KH, Cheon SH, Park S. Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study. Investig Clin Urol. 2021 May;62(3):317-323. doi: 10.4111/icu.20200380. Epub 2021 Mar 19. PMID: 33834641; PMCID: PMC8100008. 17: Ergakov DV, Martov AG. [Paradigm shift in combination therapy during the COVID-19 pandemic]. Urologiia. 2021 Mar;(1):33-38. Russian. PMID: 33818932. 18: Aishah A, Lim R, Sands SA, Taranto-Montemurro L, Wellman A, Carberry JC, Eckert DJ. Different antimuscarinics when combined with atomoxetine have differential effects on obstructive sleep apnea severity. J Appl Physiol (1985). 2021 May 1;130(5):1373-1382. doi: 10.1152/japplphysiol.01074.2020. Epub 2021 Mar 18. PMID: 33734828. 19: Harnod T, Yang YC, Chiu LT, Wang JH, Lin SZ, Ding DC. Use of bladder antimuscarinics is associated with an increased risk of dementia: a retrospective population-based case-control study. Sci Rep. 2021 Mar 1;11(1):4827. doi: 10.1038/s41598-021-84229-2. PMID: 33649451; PMCID: PMC7921664. 20: Ijitsu S, Hoashi Y, Hori K, Okimoto K, Kai T, Yoshida M, Uchida T. Preparation of Solifenacin Succinate Functional Particles Embedded in a Gelling- Swelling Layer (PEGS) and Their Formulation in Orally Disintegrating Tablets. Chem Pharm Bull (Tokyo). 2021 May 1;69(5):456-463. doi: 10.1248/cpb.c20-01009. Epub 2021 Feb 23. PMID: 33627574.